4//SEC Filing
Nabriva Therapeutics Plc 4
Accession 0001104659-17-041905
CIK 0001703287other
Filed
Jun 26, 8:00 PM ET
Accepted
Jun 27, 9:56 PM ET
Size
10.9 KB
Accession
0001104659-17-041905
Insider Transaction Report
Form 4
Khuong Chau Quang
Director10% Owner
Transactions
- Other
Ordinary Shares
2017-06-23+2,241,660→ 2,241,660 total(indirect: See footnotes) - Other
Ordinary Shares
2017-06-23+1,677,940→ 1,677,940 total(indirect: See footnotes) - Other
Stock Option
2017-06-23+10,100→ 10,100 totalExp: 2026-08-25→ Ordinary Shares (10,100 underlying)
Footnotes (6)
- [F1]Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc.
- [F2]These shares are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Advisors LLC ("Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of OrbiMed Capital GP V LLC ("GP V"), which is the sole general partner of OPI V, which is the majority member of OrbiMed Private Investments V Cooperatief U.A. ("OPI V Cooperatief"), which is the sole shareholder of OrbiMed Private Investments V-NB B.V. ("OPI V- NB"). OPI V and OPI V-NB hold ADSs and Common Shares, respectively, as described herein. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of Advisors and owns a controlling interest in Advisors.
- [F3]The Reporting Person, an employee of Advisors, has been designated by Advisors to serve on the issuer's board of directors and disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") except to the extent of his pecuniary interest therein, if any. This report on Form 3 shall not be deemed any admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act or for any other purpose.
- [F4]These shares are held of record by OPI V-NB.
- [F5]The exercise price is 6.634 Euro.
- [F6]This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017.
Documents
Issuer
Nabriva Therapeutics Plc
CIK 0001703287
Entity typeother
IncorporatedIreland
Related Parties
1- filerCIK 0001703287
Filing Metadata
- Form type
- 4
- Filed
- Jun 26, 8:00 PM ET
- Accepted
- Jun 27, 9:56 PM ET
- Size
- 10.9 KB